Diagnostics Portfolio
Roche’s Diagnostics Division is a leading supplier of in vitro diagnostics (IVDs): products used to test body fluids and tissue samples to obtain information for the purpose of diagnosing, preventing and treating disease.
Our leadership extends across the whole IVD spectrum, from centralised laboratory testing and point-of-care diagnostics to diabetes self-management. In addition, we supply cutting edge research tools to life scientists pursuing tomorrow’s medical advances. Research and development in the Business Areas focuses on disease areas where medical needs are great:
In 2012 Roche Diagnostics invested more than 900 million Swiss francs in developing technologies and products for launch in the coming years. The following key product launches are planned for 2012:
Key product launches planned for 2013
| Area | Product name | Description | Market |
|---|---|---|---|
| Instruments/devices | |||
| Laboratories | cobas 8100 | next-generation modular pre-analytics | EU |
| Diabetes Care | Accu-Chek Insight | next-generation insulin pump and blood glucose metre | EU |
| Accu-Chek Active | next-generation blood glucose metre with maltose-independent test strips | EU | |
| Life Sciences | GS FLX+ Long amplicons | software for long-read targeted sequencing for DNA variant detection | WW |
| Tests/assays | |||
| Oncology | Calcitonin | immunoassay, supports medullary thyroid cancer diagnosis and monitoring | EU |
| proGRP | immunoassay, assists in the diagnosis of small cell lung cancer | EU | |
| EGFR | PCR test, supports therapy selection for non-small cell lung cancer | US | |
| ER | IHC tissue test for breast cancer diagnosis | US | |
| CINtec PLUS Cytology | immunocytochemistry test for diagnosis of cervical pre-cancer | EU | |
| Infectious diseases | MPX 2.0 | PCR next-generation blood screening, multiplex test for HIV, HCV and HBV | US |
| HCV 2.0 | PCR next-generation HCV viral load test | US | |
| Transplantation | Cyclosporin, Tacrolimus | immunoassays for monitoring of immunosuppressive drug therapy | EU |
| Sequencing | SeqCap EZ Reagent Kits | for sample preparation for targeted next-generation sequencing | WW |
Standard type = new product/first market launch; italic type = new product/launch in additional markets.
EU = European Union; US = United States; WW = worldwide.
ALK = anaplastic lymphoma kinase; CBL = Casitas B-cell lymphoma gene; CT/NG = Chlamydia trachomatis/Neisseria gonorrhoeae; EGFR = epidermal growth factor receptor; ER = estrogen receptor; GS = Genome Sequencer; HBV = hepatitis B virus; HCV = hepatitis C virus; HE4 = human epididymis secretory protein E4; HIV = human immunodeficiency virus; IHC = immunohistochemistry; ISH = in situ hybridisation; KRAS = member of the Ras family of oncogenes; p16 = protein p16INK4a; PCR = polymerase chain reaction; proGRP = pro-gastrin-releasing peptide; RUNX1 = Runt-related transcription factor 1; TET2 = member of the TET family of oncogenes.